{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreidpd4xmwitkplp45kaj45iimls7aizth6ow4lkuf3pufkjxqpclaa",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mmhjicachot2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreiak6ru5a4ga6jy5q4ew2qddtguciocba7tygevxyt4li6nzkittoq"
    },
    "mimeType": "image/jpeg",
    "size": 87022
  },
  "path": "/news/2026-05-daily-pill-aim-measles-croup.html",
  "publishedAt": "2026-05-22T14:00:10.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "A new oral antiviral drug candidate has been developed for the treatment of diseases caused by orthoparamyxoviruses, such as measles and croup syndrome, according to a study published by researchers in the Center for Translational Antiviral Research at Georgia State University. The paper in Science Advances identifies clinical candidate GHP-88310 for urgently needed, improved orthoparamyxovirus disease management in rodent and non-rodent animal models of infection. Orthoparamyxoviruses, such as human parainfluenzaviruses, measles virus and emerging henipaviruses, pose a significant threat to human health.",
  "title": "A once-daily pill takes aim at measles, croup and other dangerous viruses"
}